• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Allogene Therapeutics (ALLO)

Common Shares
Sell: $2.33|Buy: $2.36|Change: 0.04 (-1.67%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Address

210 East Grand Avenue
South San Francisco
CA
USA
94080

Telephone

+1 650 457-2700

Website

https://www.allogene.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Allogene Therapeutics Inc Fourth Quarter Earnings Conference Call for 20262027-03-12T17:00:00
Allogene Therapeutics Inc Fourth Quarter Earnings Results for 20262027-03-12T00:00:00
Allogene Therapeutics Inc Annual Report for 20262027-03-12T00:00:00
Allogene Therapeutics Inc Third Quarter Earnings Conference Call for 20262026-11-06T17:00:00
Allogene Therapeutics Inc Third Quarter Earnings Results for 20262026-11-06T00:00:00
Allogene Therapeutics Inc Second Quarter Earnings Conference Call for 20262026-08-13T17:00:00
Allogene Therapeutics Inc Second Quarter Earnings Results for 20262026-08-13T00:00:00
Allogene Therapeutics Inc Annual General Meeting for 20262026-06-18T08:00:00
Allogene Therapeutics Inc First Quarter Earnings Conference Call for 20262026-05-13T17:00:00
Allogene Therapeutics Inc First Quarter Earnings Results for 20262026-05-13T00:00:00
Allogene Therapeutics Conference Call2026-04-13T08:30:00

Previous key dates

NameKey Date
Allogene Therapeutics Conference Call2026-04-13T08:30:00
Allogene Therapeutics Inc Fourth Quarter Earnings Conference Call for 20252026-03-12T17:00:00
Allogene Therapeutics Inc Fourth Quarter Earnings Result for 20252026-03-12T00:00:00
Allogene Therapeutics Inc Annual Report for 20252026-03-12T00:00:00
TD Cowen 46th Annual Health Care Conference2026-03-03T11:50:00
Citi's 2026 Virtual Oncology Leadership Summit2026-02-18T12:15:00
Piper Sandler 37th Annual Healthcare Conference2025-12-02T09:00:00
Jefferies Global Healthcare Conference2025-11-18T02:00:00
TD Cowen’s Immunology & Inflammation Virtual Summit2025-11-12T13:30:00
Allogene Therapeutics Inc Third Quarter Earnings Conference Call for 20252025-11-06T17:00:00
Allogene Therapeutics Inc Third Quarter Earnings Result for 20252025-11-06T00:00:00
Citi's 2025 Biopharma Back to School Summit2025-09-03T10:30:00
Allogene Therapeutics Inc Second Quarter Earnings Conference Call for 20252025-08-13T17:00:00
Allogene Therapeutics Inc Second Quarter Earnings Results for 20252025-08-13T00:00:00
Allogene Therapeutics Inc Annual General Meeting for 20252025-06-18T08:00:00
Jefferies Global Healthcare Conference2025-06-04T16:55:00
TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA2025-05-27T12:30:00
Allogene Therapeutics Inc First Quarter Earnings Conference Call for 20252025-05-13T17:00:00
Allogene Therapeutics Inc First Quarter Earnings Result for 20252025-05-13T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.